Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options.
Founded in 2021 and headquartered in Canada, the company recently secured a significant $142.00M Series B investment on 20 April 2023, from a prominent group of investors including Qiming Venture Partners USA, Versant Ventures, Amplitude Ventures, RTW Investments, VenBio Partners, Viking Global Investors, and Northview LifeSciences.
With its rapid growth and focus on innovation, Abdera Therapeutics presents an exciting opportunity for investors looking to support groundbreaking advancements in precision oncology and targeted radiotherapy.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $142.00M | 7 |
|
20 Apr 2023 |
| Series A | Unknown | 3 |
|
01 Jan 2022 |
| Seed Round | $8.00M | - | 14 Jan 2021 |
No recent news or press coverage available for Abdera Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
